Bullish Charts - Bitcoin Record Highs. Gold Record Highs. Launched in 2013, the BIT is sponsored by Alternative Currency Asset Management (ACAM), a wholly-owned subsidiary of SecondMarket Holdings, Inc. and an affiliate of SecondMarket, Inc. (custodian, marketing and distribution partner). ACAM has engaged leading service providers Ernst & Young (auditor).
Chart looks like this one is going to $17 to $20 real soon.
Daily Chart
PMO is spiking up, Bullish
Volume is Bullish
RSI is Bullish
MACD is Bullish
Accumulation is Bullish
Long!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
Pennystocks
Beat Earnings. Raised Guidance. No Debt. USA Protective GearAlpha Pro Tech, Ltd., together with its subsidiaries, engages in developing, manufacturing, and marketing a line of disposable protective apparel and infection control, and building supply products in the United States and internationally. The company operates through two segments, Building Supply and Disposable Protective Apparel. The Building Supply segment offers construction weatherization products, such as house wrap, synthetic roof underlayment, and other woven materials. The Disposable Protective Apparel segment provides shoecovers, bouffant caps, gowns, coveralls, lab coats, hoods, and frocks, as well as face masks and face shields. The company provides its products under the Alpha Pro Tech brand name, as well as under private labels. Its products are used primarily in cleanrooms; industrial safety manufacturing environments; health care facilities, such as hospitals, laboratories, and dental offices; pharmaceutical markets; and building and re-roofing sites. The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force. Alpha Pro Tech, Ltd. was founded in 1983 and is headquartered in Markham, Canada.
Net Sales of $25.5 Million, an Increase of 123.4% Year-over-Year
Provides Update on Orders for Personal Protective Equipment (PPE)
Net sales for the second quarter of 2020 were $25.5 million, compared to $11.4 million for the second quarter of 2019, up 123.4% year-over-year.
Net income for the second quarter of 2020 was $6.2 million, or $0.46 per diluted share, compared to $1.0 million, or $0.08 per diluted share, for the second quarter of 2019, up 475% on a per share basis.
NOGALES, Ariz., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Alpha Pro Tech, Ltd. (NYSE American: APT), a leading manufacturer of products designed to protect people, products and environments, including disposable protective apparel and building products, today announced financial results for the three month period ended June 30, 2020.
finance.yahoo.com
Need I say anymore? Earnings blew past Wall Street Estimates. APT raised guidance and the company has no debt.
Protective gear and N95 masks will be a part of the Worldwide dress code through 2020 and into 2021 even if a vaccine is approved because not everyone will want to take the vaccine shot.
Today's sell off was outrageous and an early Christmas gift for anyone looking for a quality company that makes protective gear & N95 masks in the USA!
Target: $32
Long!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
Bullish Charts - Huge Earrings BeatDURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase I and II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Zogenix, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.
This morning Durect reported earrings that blew away Wall Street Estimates.
Q2 EPS $0.07 Up From $(0.04) YoY, Sales $25 Million Beat $11.48 Million Estimate
Sales more than doubled estimates.
Daily Chart is Bullish
Indicators are rising, Bullish
Long!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
Rapid Recovery Respiratory Failure - COVID-19 TreatmentRelief Therapeutics Holding AG, a clinical stage biotechnology company, engages in developing treatment solutions for indications related to diabetic complications and respiratory diseases. The company is developing aviptadil, which has completed Phase II clinical trial for the treatment of sarcoidosis, an orphan pulmonary disease, as well as pulmonary hypertension; and atexakin alfa that has completed Phase I clinical trial to treat peripheral diabetic neuropathy. Relief Therapeutics Holding AG is based in Geneva, Switzerland.
RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells
- Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) was seen in patients with severe medical comorbidities after three days of treatment with RLF-100 under FDA Emergency Use IND authorization at multiple clinical sites
- Aviptadil is being developed as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes
- RLF-100 is a patented formulation of aviptadil (synthetic human Vasoactive Intestinal Polypeptide VIP), which has been granted FDA Fast Track Designation, FDA emergency use IND authorization, and an expanded access protocol
finance.yahoo.com
I think this stock could spike like Moderna
Long!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
First Higher High Since 2011. (LODE)I will be trying to get a fill around 65 cents as that is the high of the previous impulse in this massive downward channel.
As of now it looks as it could be a double bottom with strong buys from the 30 cents range.
I am attacking at the top of the channel and this can be a risky move. Comstock announced positive income for second quarter which is a bonus.
If broke 65 cents than I would look to play at the lows around 30 cents for a long term hold.
A breakout of this channel would be a strong sign.
Pennystock Wedgie. (ZOM)I will be trying to add 1% to this position around 13 cents p/share for a test on the recent bottom.
If breaks, will drop to the bottom of the wedge as we try to create the wave 5 of retracement.
Will look to add 0.5% if it does touch bottom of wedge.
This will be a longterm play with anticipation to breakout of the wedge for a impulse.
Bullish Charts - Plasma Play, FDA Approved Plasma FacilitiesADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
BREAKING NEWS TODAY - 07/30/2020
ADMA Biologics shares are trading higher following a report suggesting the company is near receiving emergency use authorization of Convalescent Plasma in COVID-19 patients.
www.benzinga.com
On July 6, 20, ADMA opened a new plasma facility and is awaiting emergency authorization for a second location.
finance.yahoo.com
With the FDA asking for everyone to donate plasma, this stock could rip!
Plasma stocks ripped today and continue to rip.
This company already is up and running one plasma facility.
Game On!
Long
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
SINTX Technologies: First 1D Golden Cross ever.SINT not only formed its first ever Golden Cross (which is a very bullish technical formation), but also closed the first 1D candle above the 1D MA200 (orange trend-line) since November 2017. This is a very bullish long-term mix for the stock and if the 3.25 Resistance breaks we are ready to buy and triple our investment at 10.00.
** If you like our free content follow our profile to get more daily ideas. **
Comments and likes are greatly appreciated.
Avinger On High Alerts. (AVGR)We analyzed this one back in june to identify a massive falling wedge on this penny stock.
We have kept it on our radar as it did breakout of the pattern and then retested the lows, treating the old Resistance a ps new support to create what looks to be a double bottom range support.
This can be signs of accumulation to push price up.
Horizontal levels are the breakout levels you will want to play and accumulate.
Remember to diversify, especially on pennystocks
Why I am Long on $MMEDFRight now one of the stocks that have my attention, (partly because of Kevin O'Leary) and the rest of its history is Mind Medicine (MindMed Inc.) They are one of the first companies finding a way to neutralize LSD while working on a DMT based therapy drug. Also, the market cap and entry is low. This is one of those stocks where you need to dig deep into the pitch deck and look at competition, market opportunities, and entry price. Right now as a biotech company, it is one of my favorite low priced biotech stocks, and as a long hold in somebody's portfolio, I don't think the risk aversion is too high. That being said, everything I say is on an opinion based basis. Please proceed with caution and invest at your own risk. Do your own due diligence.
Bullish Charts - Coil, Pennant, Flag - Vans with DronesWorkhorse Group Inc. designs, manufactures, builds, sells, and leases battery-electric vehicles and aircraft in the United States. It operates through two divisions, Automotive and Aviation. The company also develops cloud-based and real-time telematics performance monitoring systems that enable fleet operators to optimize energy and route efficiency. Its products include electric cargo vans, and medium and light-duty pickup trucks, as well as HorseFly delivery drones systems. The company was formerly known as AMP Holding Inc. and changed its name to Workhorse Group Inc. in April 2015. Workhorse Group Inc. was founded in 2007 and is headquartered in Loveland, Ohio.
Today, there was an article on Dow Jones talking about Workhorse Pairing Vans with Drones to Drive Deliveries.
www.barrons.com
On 07/24/20, there was another article, "Trucks of the Future." & "Electric Trucks are the Future."
workhorse.com - Beautiful Electric Truck
On 07/23/20, Workhorse reported a purchase order for 20, C-1000 Electric Delivery Trucks.
On 07/21/20, Workhorse talks about supplying electric trucks to the Postal Service.
Does the news get any better?
Yes, on 07/14/20, Workhorse announces Ryder will now offer the C-1000 All-Electric Step Vans for rental locations.
On the Daily Chart, it looks to me like it's flagging, Bullish
To some, it might look like an uptrending coil or a Bullish Pennant.
No matter how you look at the daily chart, it looks to me like a very Bullish setup.
RSI is turning up, Bullish
OBV is turning up, Bullish
Stochastic is turning up, Bullish
Accumulation is Bullish
I see big things coming for this company!
Long!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
Longterm Play For Sharp Corporation? (SHCAY)I've been watching this one for a while and am highly interested based off the technicals.
We have been pretty stable in price action around the previous all time low, which also resulted in a large move to the upside.
To me this looks like an accumulation play on a double bottom major support.
I am accumulating for a very long term trade, with also buys eyed at the 2.30 lows for more accumulation.
Pennystocks I like to do 1-3% of working capital in OTC markets.
RSPI:OTC P-Modeling Pt A. The Experimental Cajun Series of BioTWelcome Hyperspace Travelers..
The Cybernetic Revolution is upon us!
The world is changing..
Where will you be?
I chose to accept the cybernetic revolution early..
_______________________
This is an experimental time-series in Long-Term structural modeling.
Failure is a necessary component of success.
Entered.
Stay curious my friends..
Thanks for Pondering the Unknown with Me,
Glitch420
SESEN BIO: Buy opportunity/ emerging Golden Cross.Sesen Bio Inc has turned overbought on the 1D chart (RSI = 86.656, MACD = 0.058, ADX = 57.197) after a strong 10 day bullish sequence that broke above both the 1D MA50 and MA200 periods, but remains a buy opportunity as the MACD remains below the 9-month High. On top of that we have an emerging Golden Cross, while the price seems to be still within the Accumulation Phase.
Our short-term Target is 1.500, while if the Lower Highs trend-line breaks, we will re-buy for a 2.500 Target.
** If you like our free content follow our profile to get more daily ideas. **
Comments and likes are greatly appreciated.
AXIM Biotechnologies: But opportunity above the 1W MA50.AXIM has turned bullish on the 1W chart (RSI = 64.496, MACD = 0.100, ADX = 26.272) as after the break-out above the 1W MA50 (blue line), it is now on the 3rd straight week of trading above it. This is the first sustainable sequence above the MA50 in years, supported by a strong RSI. That break-out was made at the same time as the 1D Golden Cross, which is typically a very bullish formation.
We have added AXIM to our portfolio with a Target Zone of 3.450 - 3.8650.
** If you like our free content follow our profile to get more daily ideas. **
Comments and likes are greatly appreciated.
BIEI:OTC P-Modeling Pt 1. Cajun Swings of Valor & RedemptionWelcome Hyperspace Traveler.
This is Premier BioMedical Inc.
+3,000% gains on BIEI by Q1 of 2021. Because?... Well because its the start of 4th industrial revolution..duh.. (eye rolls).
Imagine hitting this sequence.. but don't listen to me, I am but a pond scrub a dub.
I know, I know.. The disbelief is strong...
I feel ya... But ... What if..
Mean Reversion Support, Linear Support, Adam and Eve Support, Cajun Support.
Sequence:
__________________________________
TP 1 : (0.005)
TP2 : (0.01)
-refill at .006-
TP3 : (0.066)
TP 4 : (0.12) by EOY.
Q1 2021.
________________________________________
Bullrun---> $1.00
2022.
$11.00
____________________________________
But pshhh.. no way anyone could predict that far ahead with a chart that looks like that. pfffft.
Such a mess.. or is it?
Curiosity.. it's contagious...
Follow along.. Won't wanna miss this.
Failure is a necessary component of success.
Stay safe out there.
Thanks for Pondering the Unknown with Me,
Glitch420
So, How Does Whales Actually Works?Accumulation Distribution
Pump Dump
No, whales don't day trade. Whales timeframe are years.
Whales will spend YEARS accumulating the asset.
Whales will WAIT patiently for the RIGHT TIME.
Whales will spread FUD to ensure weak hands sell.
Whales have all the money and capital to accumulate and hold.
Whales will pump and distribute the price AS HIGH AS possible to retails and suckers.
Whales own MAJORITY of the supply of an asset/stock/crypto.
Whales has always been there.
Without Whales, there is NO LIQUIDITY.
Whales provide LIQUIDITY so that the price doesn't move out of the range they want.
Whales has been operating financial market for years.
If anyone still don't believe this, I am sorry, nothing can be done anymore. There are hopeless and continue to be the slaves of this system and be the victims.
Regards.
Don't bother to reach out to me.
Moderna in Trouble - ABUS Wins Lawsuit Tied to COVID-19 DrugArbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. In addition, it develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer, an orally active agent that cause the destabilization of HBV RNAs, which leads to RNA degradation and to reduction in HBsAg levels. Further, the company engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with standard of care therapies, and in combination with each other. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
AFTER HOURS BREAKING NEWS
Moderna stock tumbled late Thursday after the biotech lost a patent battle that may jeopardize the financial future of its coronavirus vaccine.
Moderna (MRNA) challenged patents held by Arbutus Biopharma (ABUS) covering lipid nanoparticle, or LNP, technology. Lipid nanoparticles are the delivery system for messenger RNA drugs, including Moderna's coronavirus vaccine, which is known as mRNA-1273.
Despite the company's contention, the ruling could cut into profits on any Moderna drug, including mRNA-1273, says SVB Leerink analyst Mani Foroohar.
"Revenue concentration in (the coronavirus vaccine) is a central feature of the investment case for Moderna shares," Foroohar said. "Any meaningful royalty burden could hamper Moderna's pricing flexibility and margin profile vs. other players in the SARS-CoV-2 vaccine market."
Foroohar called the decision in Arbutus' favor "a disappointing turn for Moderna."
"This decision opens the door to a fascinating (and likely protracted) period of investor controversy and debate around the implications of any potential infringement of claims by Arbutus regarding Moderna's use of Lipid Nanoparticle delivery technology, and any further actions Moderna may take to defend their own (intellectual property) position and freedom to operate," he said.
NEWS: www.investors.com
Where's ABUS going? To $100.00 ...???
On the monthly chart, it looks like $9.00 might be the next stop..? At this point, I am not sure if there is a top right now for ABUS.
The news is huge for ABUS and could entitle ABUS to billions in profits and revenue from the COVID-19 vaccine.
Intelligent comments welcome.
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
Bullish Charts - FDA Grants Orphan Drug Designation for LymphomaMiragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.
LATE BREAKING NEWS AFTER HOURS - POSSIBLY A BIG SPIKE IN THE MORNING
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the Food & Drug Administration (FDA) has granted orphan drug designation to cobomarsen, for the treatment of T-cell lymphoma.
DAILY CHART IS BULLISH
OBV is Bullish
MACD turned up Bullish
RSi crossed center line and turned up, Bullish
PMO is turning up, Bullish
This little stock could spike hard.
Best of luck everyone!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
Sureshot? SHMP falling wedge to 150% ? #OTCMarkets #OTCBB #OTCQBSHMP appears to be operating in a lovely falling wedge that will likely be coming to it's end at the end of August . Sounds like a perfect late Summer setup for a 100% or more rise ? Looking at it's previous rises it has a similar appearance . Right now it's at .045 and I'd expect it to continue down this falling wedge pattern to probably .025 give or take . My target if it then goes up would be at least that local .618 fib near .0645 which would be 150% approx . but I'm no math expert ! and you should dyor - do your own research . Also I like eating shrimp ( and this is a shrimp company ! )
I would also expect a TD Seq 9 in red to be hit on the 6hr chart ( though we could definitely hit those on the 4hr or 1 day or other timeframe also . )
And the rsi 6hr should be below 30 before this is looking like a buy imo .
Keep in mind there is a Gann Fan here that could also see this go to 10 , 12 , or 15 cents but that would be a lot ! Let's keep an eye on this.
I've got Trading View alert set for 4hr rsi crossing down 30 just so I don't miss it .
Thank you .
WYY UpdateComing off strong earnings, this one has had quite a moment in the sun with over 100% gains this spring. I think this one needs some time to find stability and retrace to the Daily 150 EMA.
Decisions, DecisionsWYY has responded well to the direction of breakouts on the triangles posted below. Today, they've started the day above the trend. We should know by the end of the week if we've got a false breakout or if we're on for a big leg up.
Do not take as financial advice, this is merely for review and observation.
